Sector: MedicalLigand Pharmaceuticals Incorporated (NASDAQ: LGND)
Headlines
- Neurogen Corporation Announces Third Quarter 2009 Financial Results and Updates Operations
Nov 06, 2009 07:00 AM | LGND, NRGN
- Ligand Pharmaceuticals Announces Third Quarter Results
Nov 05, 2009 04:06 PM | LGND
- Ligand's JAK3 Research Collaboration Extended by Pfizer
Nov 05, 2009 08:30 AM | LGND, PFE
- Neurogen Corporation Announces Webcast of Third Quarter 2009 Financial Results on November 6
Nov 04, 2009 04:41 PM | LGND, NRGN
- Ligand Updates License Agreement with Exelixis
Nov 02, 2009 08:30 AM | EXEL, LGND
- Metabasis Announces Ligand to Acquire Metabasis for Cash and Contingent Value Rights
Oct 27, 2009 07:30 AM | LGND, MBRX
- Ligand to Hold Third Quarter Results Conference Call on November 5
Oct 26, 2009 04:15 PM | LGND
- Sequenom Announces Paul Maier to Become Interim Chief Financial Officer
Oct 26, 2009 04:05 PM | LGND, SQNM
- CellAura To Develop Reagents For Tag-lite(TM) GPCR Technology Platform for Cisbio Bioassays
Oct 22, 2009 12:09 PM | LGND, LSR
- KemPharm, Inc. Announces Initiation of Phase 1 Trial of KP106 for ADHD
Oct 22, 2009 08:03 AM | LGND
- Neurogen Corp. reports $1.9M loss, sells real estate
Nov 07, 2009 12:51 PM | LGND, NRGN
- Movers: GE, Nike, Discover Financial, Capital One, Goodyear
Sep 26, 2008 10:58 AM | ALOG, CHRK, CHTT, COF, CRAI, CSUN
- Ligand to Acquire Metabasis for Cash and Contingent Value Rights
Oct 27, 2009 07:53 AM | LGND, MBRX, PFE, SGP
- Ligand Terminates Long-Term Lease Obligation
Aug 10, 2009 04:52 PM | LGND, PFE, WYE
- Ligand Pharmaceuticals Announces Second Quarter Results
Aug 03, 2009 04:51 PM | KG, LGND, PFE, WYE
- Ligand and Organon Mutually Terminate Collaboration and License Agreement
Jul 30, 2009 04:20 PM | LGND
- Ligand to Hold Second Quarter Results Conference Call on August 3
Jul 23, 2009 09:01 AM | LGND
- Ligand Licenses Patents for Desulfated Heparin Technology to ParinGenix
Jun 25, 2009 08:14 AM | LGND
- Ligand Initiates Clinical Trial with the Selective Androgen Receptor Modulator LGD-4033, a Potential Treatment of Muscle and Bone Disorders
Jun 17, 2009 07:55 AM | LGND
- CORRECTING and REPLACING Ligand Pharmaceuticals Announces First Quarter Results
May 11, 2009 05:54 PM | LGND
- Ligand Pharmaceuticals Announces First Quarter Results
May 06, 2009 04:29 PM | LGND
- Ligand to Hold First Quarter Results Conference Call on May 6
Apr 28, 2009 09:12 AM | LGND
- Form 4 LAMPERT MARK N For: Aug 24 (10K)
Aug 26, 2009 06:57 PM
- Form 4 LAMPERT MARK N For: Jun 25 (10K)
Jun 29, 2009 09:31 PM
- Form 4/A KNOTT DAVID M For: Feb 17 (10K)
May 05, 2009 07:06 PM
- Form 4/A KNOTT DAVID M For: Apr 07 (10K)
May 05, 2009 07:05 PM
- Form 4 KNOTT DAVID M For: Apr 07 (10K)
Apr 09, 2009 02:19 PM
- Form 4 Dziewanowska Zofia E For: Feb 25 (10K)
Feb 27, 2009 02:36 PM
- Form 4 KNOTT DAVID M For: Feb 17 (10K)
Feb 19, 2009 09:53 PM
- Form 4 Kazmi Syed For: Feb 23 (10K)
Feb 18, 2009 03:11 PM
- Form 4 Berkman Charles S For: Feb 23 (10K)
Feb 18, 2009 03:11 PM
- Form 4 Sharp John P For: Feb 23 (10K)
Feb 18, 2009 03:11 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
LGND
|
Compare to S&P
|
| YTD |
-37.96 %
|
-45.92 %
|
| 4 Weeks |
-22.73 %
|
-23.55 %
|
| 12 Weeks |
-42.76 %
|
-44.18 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 20.00 %
|
|
EPS Growth in Last Year: 20.00 %
|
|
Sales Growth in Last Quarter: -34.28 %
|
|
Sales Growth in Last Quarter: 58.08 %
|
|
